Immediate Impact
2 from Science/Nature 58 standout
Citing Papers
The Rise of Boron-Containing Compounds: Advancements in Synthesis, Medicinal Chemistry, and Emerging Pharmacology
2024 Standout
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
2023 Standout
Works of Hank H. Yang being referenced
The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
2003
A Prospective, Open-Label Safety and Efficacy Study of Combination Treatment with Bortezomib (PS-341, Velcade™) and Melphalan in Patients with Relapsed or Refractory Multiple Myeloma
2003
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Hank H. Yang | 472 | 534 | 297 | 9 | 665 | |
| John S. Strader | 379 | 572 | 271 | 7 | 693 | |
| Tina M. Woo | 371 | 607 | 265 | 13 | 733 | |
| Denise Niewerth | 316 | 527 | 238 | 20 | 682 | |
| Annette Orleth | 399 | 612 | 191 | 13 | 827 | |
| Khristofer Garcia | 206 | 689 | 358 | 13 | 782 | |
| Julia A. Meyer | 210 | 327 | 101 | 10 | 587 | |
| Natalie D. Depcik‐Smith | 311 | 440 | 262 | 6 | 655 | |
| Emeline Cros | 209 | 377 | 186 | 13 | 617 | |
| Maureen D. Megonigal | 315 | 523 | 127 | 16 | 703 | |
| N. Roubi | 366 | 542 | 227 | 7 | 784 |
All Works
Loading papers...